MCID: INF058
MIFTS: 40

Inflammatory Myofibroblastic Tumor malady

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Inflammatory Myofibroblastic Tumor

About this section
Sources:
10Disease Ontology, 45NIH Rare Diseases, 12DISEASES, 51Orphanet, 65UMLS, 47Novoseek, 66UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Inflammatory Myofibroblastic Tumor:

Name: Inflammatory Myofibroblastic Tumor 10 45 12 51 65
Inflammatory Fibrosarcoma 45
 
Inflammatory Pseudotumor 45
Pseudotumor Inflammatory 47

Classifications:

Orphanet: 51 
Rare tumors


External Ids:

Disease Ontology10 DOID:0050905
Orphanet51 178342
UMLS via Orphanet66 C0334121
UMLS65 C0334121

Summaries for Inflammatory Myofibroblastic Tumor

About this section
NIH Rare Diseases:45 An inflammatory myofibroblastic tumor (imt) is an uncommon, presumably benign (non-cancerous) tumor made up of cells called myofibroblastic spindle cells. it usually develops in children or young adults, but can affect people of any age. an imt can occur in almost any part of the body but is most commonly found in the lung, orbit (eye socket), peritoneum (lining of the abdominal cavity and internal organs), and mesentery. signs and symptoms vary depending on the site of the tumor. some people with an imt are asymptomatic, while others may have nonspecific respiratory symptoms, fever, or pain. imts may recur, and occasionally become locally invasive and/or spread (metastasize) to other parts of the body. the underlying cause of imts is poorly understood. some cases have been linked to translocations involving the alk gene. treatment involves surgical removal when possible, although there are reports of treatment with oral steroids and radiation therapy. last updated: 2/8/2016

MalaCards based summary: Inflammatory Myofibroblastic Tumor, also known as inflammatory fibrosarcoma, is related to melanoma and anencephaly. An important gene associated with Inflammatory Myofibroblastic Tumor is ALK (Anaplastic Lymphoma Receptor Tyrosine Kinase), and among its related pathways are Smooth Muscle Contraction and Cytoskeleton remodeling Neurofilaments. Affiliated tissues include lung, eye and heart.

Disease Ontology:10 A mesenchymal cell neoplasm that has material basis in myofibroblastic cells admixed with inflammatory cells.

Related Diseases for Inflammatory Myofibroblastic Tumor

About this section

Diseases related to Inflammatory Myofibroblastic Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 362)
idRelated DiseaseScoreTop Affiliating Genes
1melanoma30.8ACTC1, ALK, DES, VIM
2anencephaly30.5ACVRL1, ALK, RNF213
3gastrointestinal stromal tumor29.7ACTC1, CD34, VIM
4liver inflammatory pseudotumor11.6
5breast cancer10.5
6cryptosporidiosis-chronic cholangitis-liver disease syndrome10.5ALK, EML4
7leukemia10.4
8absence of fingerprints congenital milia10.4ACTC1, VIM
9gingival hypertrophy10.4DES, VIM
10malignant teratocarcinosarcoma10.4DES, VIM
11familial primary hypomagnesemia with hypercalciuria and nephrocalcinosis with severe ocular involvement10.4ACTC1, VIM
12pulmonary venous return anomaly10.4ACTC1, DES
13spindle cell variant squamous cell breast carcinoma10.4DES, VIM
14prostatitis10.4
15thyroiditis10.4
16esophageal lipoma10.4ACTC1, DES, VIM
17congenital fibrosis of the extraocular muscles10.3ACTC1, DES, VIM
18benign multicystic peritoneal mesothelioma10.3ACTC1, DES, VIM
19benign mesothelioma10.3ACTC1, DES, VIM
20adult mesoblastic nephroma10.3ACTC1, DES, VIM
21pulmonary immaturity10.3ACTC1, DES, VIM
22epidermal appendage tumor10.3ACTC1, DES, VIM
23struma ovarii10.3ACTC1, DES, VIM
24kidney rhabdoid cancer10.3ACTC1, DES, VIM
25epidermolysis bullosa acquisita10.3ACTC1, DES, VIM
26vulvar angiokeratoma10.3DES, VIM
27hepatic angiomyolipoma10.3ACTC1, DES, VIM
28lung cancer10.3
29sarcoma10.3
30retinitis10.3
31glioma10.3
32severe combined immune deficiency, autosomal recessive t cell-negative, b cell-positive, nk cell-positive, il7r-related10.3ACTC1, DES, VIM
33oral tuberculosis10.3ACTC1, DES, VIM
34large cell neuroendocrine carcinoma10.3ACTC1, DES, VIM
35ovarian mucinous cystadenocarcinoma10.3ACTC1, VIM
36benign deep fibrous histiocytoma10.3ACTC1, DES
37fallopian tube carcinosarcoma10.3ACTC1, DES, VIM
38colorectal cancer10.3
39prostate cancer10.3
40hepatitis10.3
41pneumonia10.3
42lupus erythematosus10.3
43meningitis10.3
44encephalitis10.3
45hypoxia10.3
46endotheliitis10.3
47uterine corpus endometrial stromal sarcoma10.3ACTC1, DES, VIM
48childhood-onset schizophrenia10.3TPM2, TPM3
49iris spindle cell melanoma10.2ACTC1, ALK, DES, VIM
50carbon baby syndrome10.2TPM2, TPM3

Graphical network of the top 20 diseases related to Inflammatory Myofibroblastic Tumor:



Diseases related to inflammatory myofibroblastic tumor

Symptoms for Inflammatory Myofibroblastic Tumor

About this section

Drugs & Therapeutics for Inflammatory Myofibroblastic Tumor

About this section

Drugs for Inflammatory Myofibroblastic Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 15)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Doxorubicinapproved, investigationalPhase 2, Phase 3158223214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
2
MechlorethamineapprovedPhase 2, Phase 330951-75-24033
Synonyms:
.Beta.,.beta.'-Dichlorodiethyl-N-methylamine
1, 5-Dichloro-3-methyl-3-azapentane hydrochloride
126-85-2 (N-oxide)
2,2'-Dichloro-N-me
2,2'-Dichloro-N-methyldiethylamine
2,2'-Dichlorodiethyl-methylamine
2,2'-dichloro-N-methyldiethylamine
2-Chloro-N-(2-chloroethyl)-N-methylethanamine
302-70-5 (N-oxide, hydrochloride)
51-75-2
55-86-7 (HYDROCHLORIDE)
AC1L1H9H
Antimit
BRN 0605323
BSPBio_001947
Bis(2-chloroethyl)methylamine
Bis(beta-chloroethyl) methylamine
Bis(beta-chloroethyl)methylamine
C07115
C5H11Cl2N
CCRIS 447
CHEBI:28925
CHEMBL427
CID4033
Carolysine
Caryolysin
Caryolysine
Chloramine (the nitrogen mustard)
Chlorethazine
Chlormethine
Chlormethine (INN)
Chlormethine [INN:BAN]
Chlormethinum [INN-Latin]
Cloramin
Clormetina
Clormetina [INN-Spanish]
D07671
DB00888
Di(2-chloroethyl)methylamine
Dichlor amine
Dichloren
DivK1c_000759
EINECS 200-120-5
ENT-25294
Embechine
Embichin
HMS1920J15
HMS2091B04
HMS502F21
HN-2
HN2
HSDB 5083
I14-8708
IBS-L0033631
IDI1_000759
KBio1_000759
KBio2_001369
KBio2_003937
KBio2_006505
KBio3_001447
KBioGR_001448
 
KBioSS_001369
LS-7559
MBA
Me chloroethamine
Mebichloramine
Mechlorethamine
Mechlorethamine hydrochloride
Mechlorethanamine
Mechloroethamine
Mecloretamina
Mecloretamina [Italian]
Methylbis(2-chloroethyl)amine
Methylbis(beta-chloroethyl)amine
Methyldi(2-chloroethyl)amine
Mitoxine (*Hydrochloride*)
MolPort-001-785-592
Mustargen
Mustine
Mustine note
Mutagen
N,N-Bis(2-chloroethyl)-N-methylamine
N,N-Bis(2-chloroethyl)methylamine
N,N-Di(chloroethyl)methylamine
N-Lost
N-Methyl lost
N-Methyl-2,2'-dichlorodiethylamine
N-Methyl-bis(2-chloroethyl)amine
N-Methyl-bis(beta-chloroethyl)amine
N-Methyl-bis-chloraethylamin
N-Methyl-bis-chloraethylamin [German]
N-Methyl-lost
N-Methyl-lost [German]
N-methyl-bis(2-chloroethyl)amine
NCGC00091835-02
NCGC00091835-03
NCGC00091835-04
NCGC00091835-05
NCI60_041682
NINDS_000759
NSC762
Nitol (*Hydrochloride*)
Nitrogen mustard
Nitrogen mustard (HN-2)
Nitrogranulogen
SPBio_000496
SPECTRUM1500375
Spectrum2_000448
Spectrum3_000484
Spectrum4_000924
Spectrum5_001702
Spectrum_000889
Stickstofflost (*Hydrochloride*)
Stickstofflost (ebewe)
T 1024
T-1024
TL 146
UNII-50D9XSG0VR
Valchlor
beta,Beta'-dichlorodiethyl-N-methylamine
beta,beta'-Dichlorodiethyl-N-methylamine
mechlorethamine
thyldiethylamine
β,β'-dichlorodiethyl-N-methylamine
3
Cyclophosphamideapproved, investigationalPhase 2, Phase 3264350-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
 
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
4
IfosfamideapprovedPhase 2, Phase 33713778-73-23690
Synonyms:
(+-)-Ifosfamid
(+-)-Ifosphamide
(+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
(D,L)-Ifosfamide
(R,S)-Ifosphamide
(R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd
2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI)
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
3,} 2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
36341-88-5
3778-73-2
84711-20-6
A 4942
AB00513932
AC-2113
AC1L1GHW
ASTA Z 4942
Ambap3778-73-2
Asta Z 4942
BPBio1_000865
BRN 0611835
BSPBio_000785
C07047
CAS-3778-73-2
CCRIS 352
CHEBI:5864
CHEMBL1024
CID3690
Cyfos
D00343
D007069
DB01181
EINECS 223-237-3
HMS1570H07
HMS2090M12
HMS2093N07
HSDB 7023
Holoxan
Holoxan 1000
I-Phosphamide
I06-0494
IFEX (TN)
Ifex
Ifosfamid
Ifosfamida
Ifosfamida [INN-Spanish]
Ifosfamide
 
Ifosfamide (JAN/USP/INN)
Ifosfamide Sterile
Ifosfamide [USAN:INN:BAN:JAN]
Ifosfamidum
Ifosfamidum [INN-Latin]
Ifosphamide
Ifsofamide
Iphosphamid
Iphosphamid(e)
Iphosphamide
Iso Endoxan
Iso-Endoxan
Isoendoxan
Isofosfamide
Isophosphamide
Isosfamide
LS-102
LS-99799
MJF 9325
MJF-9325
MLS002154021
Mitoxana
Mitoxana, Ifex, Ifosfamide
MolPort-003-666-704
N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide
N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine
NCGC00016639-01
NCGC00179435-01
NCI-C01638
NCI60_000233
NPFAPI-04
NSC 109,724
NSC 109724
NSC-109,724
NSC-109724
NSC109,724
NSC109724
Naxamide
Prestwick0_000833
Prestwick1_000833
Prestwick2_000833
Prestwick3_000833
S1302_Selleck
SMR001233348
SPBio_002706
STL058690
UNII-UM20QQM95Y
WLN: T6NPOTJ AM2G BO B2G
Z 4942
Z-4942
Z4942
ifosfamide
isosfamide
{3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,
5
DoxilApproved June 1999Phase 2, Phase 3158231703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
6Antineoplastic Agents, AlkylatingPhase 2, Phase 33406
7Topoisomerase InhibitorsPhase 2, Phase 34081
8Isophosphamide mustardPhase 2, Phase 3371
9Anti-Bacterial AgentsPhase 2, Phase 39140
10Antibiotics, AntitubercularPhase 2, Phase 35971
11Alkylating AgentsPhase 2, Phase 33582
12
CrizotinibapprovedPhase 292877399-52-511626560, 10366136, 10366137, 10366138, 10366139, 10366140, 10366141
Synonyms:
(R)-Crizotinib
C-Met/HGFR Tyrosine Kinase Inhibitor PF-02341066
C-Met/Hepatocyte Growth Factor Receptor Tyrosine Kinase Inhibitor PF-02341066
Crizotinib
Crizotinibum
 
MET Tyrosine Kinase Inhibitor PF-02341066
PF 2341066
PF-02341066
PF-2341066
Xalkori
crizotinib
13Protein Kinase InhibitorsPhase 2, Phase 13162
14MitogensPhase 1, Phase 21386
15
CeritinibapprovedPhase 1361032900-25-6
Synonyms:
2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2- isopropylsulfonyl)phenyl) pyrimidine-2,4-diamine
LDK378
 
N-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamide
Zykadia
céritinib

Interventional clinical trials:

idNameStatusNCT IDPhase
1Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by SurgeryRecruitingNCT02180867Phase 2, Phase 3
2CREATE: Cross-tumoral Phase 2 With CrizotinibRecruitingNCT01524926Phase 2
3Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung CancerRecruitingNCT01625234Phase 1, Phase 2
4Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1RecruitingNCT02034981Phase 2
5A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113Active, not recruitingNCT01449461Phase 1, Phase 2
6Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)RecruitingNCT01742286Phase 1
7Cohort Study of IgG4RDRecruitingNCT01670695Phase 0

Search NIH Clinical Center for Inflammatory Myofibroblastic Tumor

Genetic Tests for Inflammatory Myofibroblastic Tumor

About this section

Anatomical Context for Inflammatory Myofibroblastic Tumor

About this section

MalaCards organs/tissues related to Inflammatory Myofibroblastic Tumor:

33
Lung, Eye, Heart, Breast, Bone, Endothelial, Colon

Animal Models for Inflammatory Myofibroblastic Tumor or affiliated genes

About this section

MGI Mouse Phenotypes related to Inflammatory Myofibroblastic Tumor:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes

Publications for Inflammatory Myofibroblastic Tumor

About this section

Articles related to Inflammatory Myofibroblastic Tumor:

(show top 50)    (show all 485)
idTitleAuthorsYear
1
Hyperuricemia is independently associated with increased risk of atrial fibrillation: A meta-analysis of cohort studies. (25777070)
2015
2
Diversity in sequence-dependent control of GRO chemokine mRNA half-life. (23519936)
2013
3
Moderate-to-vigorous physical activity in individuals with psoriasis: associations with body surface area and subjective disease severity. (24005141)
2013
4
Cutaneous calcinosis in juvenile dermatomyositis. (23608558)
2013
5
The CLOCK 3111T/C SNP is associated with morning gastric motility in healthy young women. (22709985)
2012
6
Stage III malignant mixed MA1llerian tumor of the fallopian tube: a case of 5-year survival after optimal debulking and adjuvant chemotherapy with paclitaxel plus carboplatin. (22795114)
2012
7
Ischemic heart disease in patients undergoing dialysis. (23299034)
2012
8
Partial resection of intravenous leiomyomatosis with cardiac extension. (21225399)
2011
9
Administration of intrapericardial tissue adhesive after cardiac rupture and cardiac tamponade. (19201492)
2011
10
Rare pediatric adrenocortical carcinoma with oncocytic change: a cytologic dilemma. (21181300)
2011
11
N-terminal interaction domain implicates PAK4 in translational regulation and reveals novel cellular localization signals. (20578242)
2010
12
Small cell carcinoma of the urinary bladder. (20017108)
2010
13
Paroxysmal dyskinesia with dAcjA vu aura. (20160226)
2010
14
Lipoprotein lipase activity and prediction for survival in lung cancer. (20430258)
2010
15
Toll-like receptor 2 gene polymorphisms, pulmonary tuberculosis, and natural killer cell counts. (20113509)
2010
16
The use of infliximab in a patient with idiopathic granulomatous hepatitis. (21686858)
2009
17
Soluble gp130, an antagonist of IL-6 transsignaling, is elevated in uveitis aqueous humor. (18469182)
2008
18
N-myristoyltransferase: a novel target. (18289097)
2008
19
Putative stem cells with an embryonic character isolated from the ovarian surface epithelium of women with no naturally present follicles and oocytes. (18452550)
2008
20
Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. (18172266)
2008
21
A novel 22-bp deletion mutation in a Chinese family with X-linked hypohidrotic ectodermal dysplasia. (18427821)
2008
22
Vasopressin V2-receptor antagonist, tolvaptan, for treatment of heart failure]. (17571379)
2007
23
Mammalian glycerophosphodiester phosphodiesterases. (17690467)
2007
24
Coccidioidomycosis in persons infected with HIV-1. (17363429)
2007
25
Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers. (16941478)
2006
26
Evidence of calcium-dependent pathway in the regulation of human beta1,3-glucuronosyltransferase-1 (GlcAT-I) gene expression: a key enzyme in proteoglycan synthesis. (16807373)
2006
27
BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study. (14722037)
2004
28
West Nile viral encephalitis: a case study. (15366542)
2004
29
Transcriptional regulation of dentin matrix protein 1 by JunB and p300 during osteoblast differentiation. (15308641)
2004
30
Novel selective and metabolically stable inhibitors of anandamide cellular uptake. (12732359)
2003
31
Convergence of RNA cis elements and cellular polyadenylation factors in the regulation of human cytomegalovirus UL37 exon 1 unspliced RNA production. (14610195)
2003
32
Acute myelogenous leukemia with the t(3;12)(q26;p13) translocation: case report and review of the literature. (12555218)
2003
33
The role of arthroscopic bursectomy in the treatment of trochanteric bursitis. (12209419)
2002
34
Subcutaneous administration of insulin-like growth factor (IGF)-II/IGF binding protein-2 complex stimulates bone formation and prevents loss of bone mineral density in a rat model of disuse osteoporosis. (12162999)
2002
35
Giant coronary artery aneurysm arising from sinus node artery. (11603468)
2001
36
Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease. (11231980)
2001
37
Endothelial cell-specific regulation of the murine endothelin-1 gene. (10976773)
2000
38
Gastrin secretion by ovine antral mucosa in vitro. (10936763)
2000
39
Phenotypic features, androgen receptor binding, and mutational analysis in 278 clinical cases reported as androgen insensitivity syndrome. (10690872)
2000
40
Stroke in paced patients with sick sinus syndrome: influence of left atrial function and size. (10516407)
1999
41
Archival, formalin-fixed tissue: its use in the study of Alzheimer's type changes. (9496540)
1998
42
Mutation pattern in the Bruton's tyrosine kinase gene in 26 unrelated patients with X-linked agammaglobulinemia. (9143921)
1997
43
Identification of a new missense mutation in Japanese phenylketonuric patients. (8068076)
1993
44
Oncostatin M binds the high-affinity leukemia inhibitory factor receptor. (1536831)
1992
45
Cortical deafness cannot account for the inability of Japanese macaques to discriminate species-specific vocalizations. (2920286)
1989
46
Giant congenital hydronephrosis and isolated tuberculous granulomatous pyelitis. (3585026)
1987
47
Lethal forms of hereditary collagen disorders: Ehlers-Danlos syndrome type IV and congenital osteogenesis imperfecta. (7163269)
1982
48
Serological evidence for the association of Akabane virus with epizootic bovine congenital arthrogryposis and hydranencephaly syndromes in New South Wales. (1164273)
1975
49
Hemodynamics of the experimental dumping syndrome. (5822759)
1969
50

Variations for Inflammatory Myofibroblastic Tumor

About this section

Expression for genes affiliated with Inflammatory Myofibroblastic Tumor

About this section
Search GEO for disease gene expression data for Inflammatory Myofibroblastic Tumor.

Pathways for genes affiliated with Inflammatory Myofibroblastic Tumor

About this section

GO Terms for genes affiliated with Inflammatory Myofibroblastic Tumor

About this section

Cellular components related to Inflammatory Myofibroblastic Tumor according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1stress fiberGO:000172510.5TPM3, TPM4
2cytoskeletonGO:00058569.8DES, TPM3, TPM4
3intermediate filament cytoskeletonGO:00451119.8DES, VIM

Biological processes related to Inflammatory Myofibroblastic Tumor according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1muscle filament slidingGO:00300499.9ACTC1, VIM

Sources for Inflammatory Myofibroblastic Tumor

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet